against Gram-Negative Bacteria Protein and CD14 in Immune Responses Critical Role of Lipopolysaccharide-Binding

LPS-binding protein (LBP) and CD14 potentiate cell activation by LPS, contributing to lethal endotoxemia. We analyzed the contribution of LBP/CD14 in models of bacterial infection. Mice pretreated with mAbs neutralizing CD14 or LBP showed a delay in TNF- (cid:1) production and died of overwhelming infection within 24 h, after a challenge with 250 CFU of virulent Klebsiella pneumoniae . Blockade of TNF- (cid:1) also increased lethality, whereas pretreatment with TNF- (cid:1) protected mice, even in the presence of LBP and CD14 blockade. Anti-LBP or anti-CD14 mAbs did not improve or decrease lethality with a higher inoculum (10 5 K. pneumoniae ) and did not affect outcome following injections of low or high inocula of Escherichia coli O111. These results point to the essential role of LBP/CD14 in innate immunity against virulent bacteria. The Journal of Immunology, 2001, 167: 2759– 2765.

[1]  A. Cross,et al.  PRETREATMENT WITH RECOMBINANT MURINE TUMOR NECROSIS FACTOR cdCACHECTIN AND MURINE INTERLEUKIN 1 a PROTECTS MICE FROM LETHAL BACTERIAL INFECTION , 2003 .

[2]  L. Moldawer,et al.  Cytokine signaling--regulation of the immune response in normal and critically ill states. , 2000, Critical care medicine.

[3]  C. Wennerås,et al.  Blockade of CD14 Increases Shigella-Mediated Invasion and Tissue Destruction1 , 2000, The Journal of Immunology.

[4]  C. Bogdan,et al.  Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity. , 2000, Current opinion in immunology.

[5]  K. Frei,et al.  Reduced antilisterial activity of TNF‐deficient bone marrow‐derived macrophages is due to impaired superoxide production , 1999, European journal of immunology.

[6]  R. Landmann,et al.  Monoclonal antibodies to murine lipopolysaccharide (LPS)-binding protein (LBP) protect mice from lethal endotoxemia by blocking either the binding of LPS to LBP or the presentation of LPS/LBP complexes to CD14. , 1999, Journal of immunology.

[7]  Y. Adachi,et al.  Inhibition by a CD14 monoclonal antibody of lipopolysaccharide binding to murine macrophages , 1999 .

[8]  D. O'Brien,et al.  Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae infections. , 1999, Infection and immunity.

[9]  L. Kline,et al.  Phagocytosis of Gram‐negative bacteria by a unique CD14‐dependent mechanism , 1997, Journal of leukocyte biology.

[10]  G. Rune,et al.  Lipopolysaccharide-binding protein is required to combat a murine Gram-negative bacterial infection , 1997, Nature.

[11]  T. van der Poll,et al.  Passive immunization against tumor necrosis factor-alpha impairs host defense during pneumococcal pneumonia in mice. , 1997, American journal of respiratory and critical care medicine.

[12]  T. Standiford,et al.  Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumonia , 1996, Infection and immunity.

[13]  A. Kallies,et al.  Monocytes can phagocytose Gram-negative bacteria by a CD14-dependent mechanism. , 1996, Journal of immunology.

[14]  R. Ulevitch,et al.  Antibodies against CD14 protect primates from endotoxin-induced shock. , 1996, The Journal of clinical investigation.

[15]  J. Silver,et al.  Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. , 1996, Immunity.

[16]  R. Zinkernagel,et al.  Multiple immune abnormalities in tumor necrosis factor and lymphotoxin-α double-deficient mice , 1996 .

[17]  C. Jongeneel,et al.  Reactivity of murine and human recombinant LPS-binding protein (LBP) within LPS and gram negative bacteria. , 1995, Journal of inflammation.

[18]  D. Le Roy,et al.  Results of passive and active immunization directed against ferric aerobactin in experimental enterobacterial infections in mice and chickens. , 1995, Research in microbiology.

[19]  M. Glauser,et al.  Mode of action of anti-lipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. van Furth,et al.  Anti-tumor necrosis factor antibodies inhibit the influx of granulocytes and monocytes into an inflammatory exudate and enhance the growth of Listeria monocytogenes in various organs. , 1994, The Journal of infectious diseases.

[21]  M. Glauser,et al.  Lipopolysaccharide-binding protein as a major plasma protein responsible for endotoxemic shock. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Zinkernagel,et al.  Mice lacking the tumour necrosis factor receptor 1 are resistant to IMF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes , 1993, Nature.

[23]  S. Opal,et al.  Choice of bacteria in animal models of sepsis , 1993, Infection and immunity.

[24]  H. Langstein,et al.  Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis. , 1991, The Journal of clinical investigation.

[25]  B. Echtenacher,et al.  Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. , 1990, Journal of immunology.

[26]  R. Ulevitch,et al.  Structure and function of lipopolysaccharide binding protein. , 1990, Science.

[27]  R. Ulevitch,et al.  CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. , 1990, Science.

[28]  Y. Terada,et al.  Protective effect of recombinant tumor necrosis factor-α in murine salmonellosis. , 1990 .

[29]  T. Raffin,et al.  Effects of tumor necrosis factor on PMN chemotaxis, chemiluminescence, and elastase activity. , 1989, The Journal of laboratory and clinical medicine.

[30]  E. A. Havell.  Evidence that tumor necrosis factor has an important role in antibacterial resistance. , 1989, Journal of immunology.

[31]  J. Larrick,et al.  Enhancement of neutrophil superoxide production by preincubation with recombinant human tumor necrosis factor. , 1987, Journal of immunology.